Akston's NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study

ACVIM 2026 forum data showed AKS-548d and AKS-734 triggered sustained anti-NGF antibody responses with functional neutralization of NGF binding to TrkA. The results also reported clinically meaningful reductions in canine osteoarthritis pain, suggesting potential efficacy signals for the programs.

Analysis

ACVIM 2026 forum data showed AKS-548d and AKS-734 triggered sustained anti-NGF antibody responses with functional neutralization of NGF binding to TrkA. The results also reported clinically meaningful reductions in canine osteoarthritis pain, suggesting potential efficacy signals for the programs.